Hikal LimitedAugust 1, 2019

FDA 483 - Hikal Limited - August 01, 2019

View on Dashboard

Discuss this record with AI

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Hikal Limited

Record Details

An inspection of Hikal Limited, an active pharmaceutical manufacturer in Anekal Taluk, Bangalore, revealed significant deficiencies in their laboratory procedures and record-keeping practices. Specifically, records for microbial testing were not completed at the time of performance, and documentation for bioburden analysis was found to be inadequate. These issues impact drug substances intended for both European and US markets.

Company: Hikal Limited
Inspection Date: August 1, 2019
Product Type: Drugs
Office: Office of Biological Products Operations - Division I
Person: Maria Estrella (investigator)

Open in Dashboard

ID · 95f89445-c3bd-4ff9-a0f2-92f1aeb9df09